19 completed, 6 recruiting, 6 terminated, 4 unknown. 10 Not applicable, 10 Phase 2, 7 Phase 3, 4 Phase 1.
Follow Acute Chest Syndrome: new trials by email Literature Review of Acute Chest Syndrome trials Research Report on Acute Chest Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPAP for Hypoxemic Acute Chest Syndrome in Sickle Cell Disease O2+CPAP group - Sickle Cell Disease (SCD), Acute Chest Syndrome (ACS) | Not applicable | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 140 | 2026-09-01 | 2026-07-23 |
| Pleuropulmonary Ultrasound Imaging in Patients With Sickle Cell Disease in a Vaso-occlusive Crisis. "ECHODREP" Pleuropulmonary ultrasound - Sickle Cell Disease (SCD), Vaso-Occlusive Crises | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 200 | 2026-09-01 | 2026-08-24 | |
| Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease Lidocain, Placebo, Standard of care - Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Recruiting | Nantes University Hospital | 104 | 2026-07-03 | 2026-09-09 |
| Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care Injection of iohexol for glomerular filtration rate (GFR) measurement - Sickle Cell Disease, Glomerular Hyperfiltration | Not applicable | Recruiting | University Hospital, Tours | 100 | 2026-03-05 | 2026-03-10 |
| Awake Prone Positioning for Severe Acute Chest Syndrome Awake prone positioning (APP) - Acute Chest Syndrome, Sickle Cell Anemia | Not applicable | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 15 | 2026-01-01 | 2025-09-02 |
| Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease Tocilizumab (RoActemra®, 20 mg/mL)., Placebo (NaCl 0.9%) - Sickle Cell Disease, Acute Chest Syndrome | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 130 | 2025-08-27 | 2026-06-24 |
| Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis CSL889, Placebo - Sickle Cell Disease Vaso-occlusive Crisis | Phase 2 | Recruiting | CSL Behring | 70 | 2025-07-10 | 2026-10-08 |
| Ultrasound Acute Chest Syndrome Sickle Cell Disease Point of Care Ultrasound - Acute Chest Syndrome, Sickle Cell Disease | Not applicable | Completed | Indiana University | 27 | 2025-04-08 | 2026-09-02 |
| Lung Ultrasound in Pediatric Acute Chest Syndrome lung ultrasound - Sickle Cell Disease | Unknown | Assistance Publique - Hôpitaux de Paris | 60 | 2024-06-30 | 2024-07-11 | |
| Early-goal Directed Automated Red Blood Cell Exchange for Acute Chest Syndrome in Sickle Cell Disease Red blood cell EXchange (REX) - Acute Chest Syndrome | Not applicable | Unknown | Assistance Publique - Hôpitaux de Paris | 130 | 2024-03-01 | 2024-01-22 |
| Use of Macrolides in Acute Chest Syndrome: A Multicenter Retrospective Study Sickle Cell Disease, Acute Chest Syndrome | Completed | Centre Hospitalier de Saint-Denis | 250 | 2023-06-01 | 2025-06-25 | |
| Tocilizumab for Acute Chest Syndrome Tocilizumab - Sickle Cell Disease, Acute Chest Syndrome | Phase 2 | Recruiting | University of Chicago | 200 | 2023-04-10 | 2026-09-15 |
| Evaluation of Therapeutic Adherence to Inciting Spirometry in Sickle Cell Patients Sickle Cell Disease | Completed | Centre Hospitalier Intercommunal Creteil | 15 | 2021-01-01 | 2021-02-23 | |
| Daily Vitamin D for Sickle-cell Respiratory Complications Daily oral vitamin D3, 3,333 IU, Monthly oral vitamin D3, 100,000 IU, Placebo oral tablet - Sickle Cell Disease, Anemia, Sickle Cell | Phase 2 | Completed | Columbia University | 58 | 2020-09-15 | 2025-09-24 |
| Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease. Brilinta, Placebo - Sickle Cell Disease | Phase 3 | Withdrawn | AstraZeneca | 2020-06-30 | 2020-07-15 | |
| Combined Use of a Respiratory Broad Panel Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Hospitalized Sickle-cell Adults With Acute Chest Syndrome. Intervention: Combined use of a respiratory broad panel multiplex PCR and procalcitonin, Control: usual antibiotic treatment - Acute Chest Syndrome, Sickle Cell Disease | Not applicable | Completed | Assistance Publique - Hôpitaux de Paris | 72 | 2020-06-02 | 2025-03-24 |
| Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin Aspirin, Atorvastatin, Placebo Aspirin - Acute Chest Syndrome | Phase 3 | Terminated | Dr. med. Mahir Karakas | 68 | 2020-02-21 | 2022-05-24 |
| Early Diagnosis of Sickle Acute Chest Syndrome Using a Combination of Plasma Bimarkers and Chest Imaging Sickle Cell Disease (SCD) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 65 | 2018-02-27 | 2023-07-17 | |
| sPLA2 in EBC During Acute Chest Syndrome Exhaled Breath Condensate (EBC), Plasma Sample - Sickle Cell Disease, Acute Chest Syndrome | Completed | Virginia Commonwealth University | 6 | 2018-01-19 | 2018-09-26 | |
| Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome Defibrotide - Sickle Cell Disease, Acute Chest Syndrome | Phase 2 | Completed | New York Medical College | 20 | 2018-01-12 | 2023-12-08 |
Showing 20 of 40. Sign in to see all of them.
Anemia, Sickle Cell (34) · Vaso-Occlusive Crises (11) · Asthma (3) · Hypertension, Pulmonary (3) · Respiratory Tract Infections (2) · Vitamin D Deficiency (2) · Acute Kidney Injury (1) · Acute Lung Injury (1) · Agnosia (1) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Avitaminosis (1) · Emergencies (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (40) · Genetic Diseases, Inborn (40) · Hematologic Diseases (40) · Hemic and Lymphatic Diseases (40) · Anemia (39) · Anemia, Hemolytic (39) · Anemia, Hemolytic, Congenital (39) · Hemoglobinopathies (39) · Lung Diseases (39) · Respiration Disorders (39) · Respiratory Tract Diseases (39) · Anemia, Sickle Cell (6) · Pathological Conditions, Signs and Symptoms (4) · Bronchial Diseases (3) · Cardiovascular Diseases (3)
Cholecalciferol (2) · Nitric Oxide (2) · Standard of Care (2) · tocilizumab (2) · Administration, Oral (1) · Albuterol (1) · Aspirin (1) · Atorvastatin (1) · Azithromycin (1) · Blood Transfusion (1) · Dexamethasone (1) · Endothelium-Dependent Relaxing Factors (1) · Glomerular Filtration Rate (1) · Hemopexin (1) · Heparin (1)
Assistance Publique - Hôpitaux de Paris (11) · National Heart, Lung, and Blood Institute (NHLBI) (3) · Albert Einstein College of Medicine (1) · Alexhander Izhaki (1) · Anthera Pharmaceuticals (1) · AstraZeneca (1) · CSL Behring (1) · Carelon Research (1) · Centre Hospitalier Intercommunal Creteil (1) · Centre Hospitalier de Saint-Denis (1) · Children's Hospital Medical Center, Cincinnati (1) · Columbia University (1) · Craig Seaman (1) · Dr. med. Mahir Karakas (1) · Duke University (1)
United States (20) · France (14) · United Kingdom (2) · Germany (1) · Guadeloupe (1) · Israel (1) · Turkey (Türkiye) (1)
Alexander J Izhaki, MD (1) · Alexandre Elabbadi, MD (1) · Anders Berggren, MD, PhD (1) · Armand Mekontso Dessap, MD, PhD (1) · Arun S Shet, M.D. (1) · Bernard Maitre, MD, PhD (1) · Charles Quinn, MD (1) · Claire Heilbronner, MD, PhD (1) · Craig D Seaman, MD (1) · Davis D Michael, PhD (1) · Deepa Manwani, MD (1)
PMID 24916507, PMID 26589907, PMID 19536844, PMID 20378559, PMID 21275961, PMID 21848879, PMID 22231150, PMID 22463614, PMID 22804353, PMID 23828202, PMID 26431718, PMID 29419434, PMID 29712666, PMID 33661274, PMID 37877609, PMID 39659429, PMID 39995490, PMID 40209087, PMID 41410575
U54HL070587 (2), 2023 (1), U10HL083721 (1)